Godavari Biorefineries Share Price Gains Over 6% as Japanese Patent Granted for Cancer Treatment Compound

Godavari Biorefineries Limited has announced the granting of a Japanese patent for its innovative compound, "5-Hydroxy-1,4-Naphthalenedione," aimed at treating cancer.  

This development marks a significant milestone in the company's research and development efforts. 

Patent Granted for Cancer Treatment Compound 

The Japanese Patent Office has granted Godavari Biorefineries a patent for "5-Hydroxy-1,4-Naphthalenedione," a compound designed for cancer treatment.  

This compound exhibits inhibitory effects on cancer and cancer stem cells, showing efficacy against multiple cancer types, including breast and prostate cancer. 

Importance of Patent in Oncology 

The patent strengthens Godavari Biorefineries' position in the oncology sector by protecting its intellectual property and potentially opening new avenues for treatment options.  

The compound's efficacy against various cancer types underscores its potential impact in the medical field. 

Patent Registration Date 

The patent was officially registered on May 26, 2026, as confirmed by the Japan Patent Office. This registration marks the culmination of the application process that began on October 26, 2021. 

Read More: RIL Share Price Surges as Jio Platforms Surges into Global Top 20 in Latest WIPO Patents Ranking! 

Godavari Biorefineries Share Price Performance 

As of June 16, 2026, at 12:30 PM, Godavari Biorefineries share price on NSE was trading at ₹302.75 up by 6.45% from the previous closing price. 

Conclusion 

Godavari Biorefineries' acquisition of a Japanese patent for its cancer treatment compound, "5-Hydroxy-1,4-Naphthalenedione," highlights its commitment to advancing oncology solutions. The patent, registered on May 26, 2026, underscores its potential impact in cancer treatment. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.